Photochromically-controlled, reversibly-activated MRI and optical contrast agent - PubMed (original) (raw)

. 2007 Apr 7:(13):1331-3.

doi: 10.1039/b616991k. Epub 2007 Jan 18.

Affiliations

Photochromically-controlled, reversibly-activated MRI and optical contrast agent

Chuqiao Tu et al. Chem Commun (Camb). 2007.

Abstract

The contrast agent which tethers a spiropyran group to a Gd-DO3A moiety has higher relaxivity and fluorescence intensity in the dark; the relaxivity and fluorescence intensity decrease after irradiation with visible light.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Absorption spectrum of compound 5 (7.665 × 10-5 M) in water. 1: in the dark; 2: irradiated with visible light for 1 minute; 3: irradiated with UV at 365 nm for 10 minutes after being irradiated with visible light for 1 minute; 4: in the dark for 20 minutes after being irradiated with visible light for 1 minute.

Fig. 2

Fig. 2

Emission spectrum of compound 5 (7.665 × 10-5 M) in water with excitation at 500 nm.

Scheme 1

Scheme 1

Synthesis of compound 5.

Scheme 2

Scheme 2

Proposed isomerization of Gd-SPDO3A (left) and Gd- MCDO3A (right).

References

    1. Westbrook C, Roth CK, Talbot J. MRI in practice. 3rd edn Blackwell Publishing Inc.; Malden, MA: 2005.
    1. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Chem. Rev. 1999;99:2293. -PubMed
    1. Blankenberg FG. J. Cell. Biochem. 2003;90:443. -PubMed
    1. Louie AY, Hüber M, Ahrens ET, Rothbächer U, Moats R, Jacobs R, Fraserand SE, Meade TJ. Nat. Biotechnol. 2000;18:321. -PubMed
    2. Alauddin MM, Louie AY, Shahinian A, Meade TJ, Conti PS. Nucl. Med. Biol. 2003;30:261. -PubMed
    3. Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H. Eur. J. Radiol. 2003;46:33. -PubMed
    4. Aime S, Cabella C, Colombatto S, Crich SG, Gianolio E, Maggioni F. J. Magn. Reson. Imaging. 2002;16:394. -PubMed
    1. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S. Mol. Cell. Biol. 1987;7:725. -PMC -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources